3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
27
Lung Neoplasms
5
Brain Neoplasms
4
Esophageal Neoplasms
2
EGF-R Positive Non-Small Cell Lung Cancer
2
Adenocarcinoma of Lung
2
Squamous Cell Carcinoma of Lung
1
Plasma EGFR Mutation-positive Lung Cancer
1
Non-small Cell Lung Cancer Metastatic
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
NSCLC
1
Drug-Related Side Effects and Adverse Reactions
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
icotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Plasma EGFR Mutation-positive Lung Cancer
×
icotinib
×
Clear all
NCT03346811
2017-11-17
CHALLENGE
Betta Pharmaceuticals Co., Ltd.
Phase 2
Unknown
120 enrolled